Targeted systemic radiotherapy of pheochromocytoma and medullary thyroid cancer

Seminars in Nuclear Medicine

Volumn 41, Issue 5, 2011, Pages 369-373

  Divgi, Chaitanya ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CARCINOEMBRYONIC ANTIBODY; LUTETIUM 177; SOMATOSTATIN RECEPTOR; YTTRIUM 90;

ADULT; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG STRUCTURE; HUMAN; ISOTOPE LABELING; LUNG TOXICITY; NEUROBLASTOMA; PHEOCHROMOCYTOMA; PROGRESSION FREE SURVIVAL; RADIATION ABSORPTION; RADIATION DOSE; RADIATION EXPOSURE; RADIATION HAZARD; RADIATION RESPONSE; RADIATION SAFETY; RADIOACTIVITY; RADIOIMMUNOTHERAPY; REVIEW; SYSTEMIC THERAPY; THYROID CANCER; THYROID MEDULLARY CARCINOMA;

HUMANS; PHEOCHROMOCYTOMA; RADIOISOTOPES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SAFETY; THYROID NEOPLASMS;

EID: 79960906082     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2011.05.004     Document Type: Review

References (28)

1. Van Nostrand D, Atkins F, Moreau S, et al: Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma. Thyroidology 19:1093-1098, 2009
2. Song H, He B, Prideaux A, et al: Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med 47:1985-1994, 2006 (Pubitemid 47544986)
3. Barrett JA, Joyal JL, Hillier SM, et al: Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharm 25:299-308, 2010
4. Girling D, Parmar M, Stenning S, et al: Clinical Trials in Cancer: Principles and Practice (ed 1). Oxford, Oxford University Press, 2003
5. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
6. Matthay KK, Tan JC, Villablanca JG, et al: Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: A new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 24:500-506, 2006 (Pubitemid 46630470)
7. Bodei L, Handkiewicz-Junak D, Grana C, et al: Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 19:65-71, 2004 (Pubitemid 38352287)
8. O'Donoghue JA, Baidoo N, Deland D, et al: Hematologic toxicity in radioimmunotherapy: Dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm 17:435-443, 2002
9. Leeper RD: The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab 36:1143-1152, 1973
10. Wessels BW, Bolch WE, Bouchet LG, et al: Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multi-institutional comparison. J Nucl Med 45:1725-1733, 2004 (Pubitemid 47618483)
11. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al: Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46 Suppl 1:62S-66S, 2005 (Pubitemid 47619020)
12. DuBois SG, Matthay KK: Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 35 Suppl 1:S35-S48, 2008
13. Postema EJ, McEwan AJ: Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults. Cancer Biother Radiopharm 24:519-525, 2009
14. Gedik GK, Hoefnagel CA, Bais E, et al: 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 35:725-733, 2008
15. Muxí A, Paredes P, Navales I, et al: Diagnostic cutoff points for (123)I-MIBG myocardial scintigraphy in a Caucasian population with Parkinson's disease. Eur J Nucl Med Mol Imaging 38:1139-1146, 2011
16. Delpassand ES, Sims-Mourtada J, Saso H, et al: Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm 23:292-300, 2008 (Pubitemid 351931457)
17. Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28:1652-1659, 2010
18. Sharkey RM, Hajjar G, Yeldell D, et al: A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46:620-633, 2005 (Pubitemid 41716407)
19. Chatal JF, Campion L, Kraeber-Bodéré F, et al; French Endocrine Tumor Group: Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24:1705-1711, 2006 (Pubitemid 46622142)
20. Bombardieri E, Giammarile F, Aktolun C, et al, European Association for Nuclear Medicine: 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 37:2436-2446, 2010
21. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed June 10, 2011
22. Navalkissoor S, Alhashimi DM, Quigley AM, et al: Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 37:904-912, 2010
23. Giammarile F, Chiti A, Lassmann M, et al: EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 35:1039-1047, 2008
24. King J, Quinn R, Glenn DM, et al: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113:921-929, 2008
25. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
26. O'Donoghue JA, Bardiès M, Wheldon TE: Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36:1902-1909, 1995
27. Lucignani G: Alpha-particle radioimmunotherapy with astatine-211 and bismuth-213. Eur J Nucl Med Mol Imaging 35:1729-1733, 2008
28. Vaidyanathan G, Affleck DJ, Alston KL, et al: A kit method for the high level synthesis of [211At]MABG. Bioorg Med Chem 15:3430-3436, 2007 (Pubitemid 46529264)